Cornucopia Biosciences

Cornucopia Biosciences is a software company specializing in laboratory automation, transforming natural language into validated scientific protocols executed by liquid handling systems, thereby enhancing laboratory efficiency. Cornucopia Biosciences, founded in 2025 in San Francisco, US, focuses on automating laboratory workflows. The company raised USD 200,000 in pre-seed funding from Antler on November 13, 2025, marking its first investment milestone. The founder's history and previous ventures are not disclosed.

Cornucopia Bio specializes in automating laboratory workflows by transforming plain English into literature-validated protocols, which are then executed on liquid handling systems. The core offering of the company centers around its AI-driven platform that streamlines the process of protocol generation, execution, and results analysis, thus addressing the challenges of time-consuming manual scripting and operational inefficiencies in laboratories. The platform enables researchers to describe their experimental goals in natural language, from which validated protocols are generated and dispatched to various connected liquid handlers such as Opentrons, Hamilton, Tecan, and Agilent. Cornucopia's technology is designed for a diverse client base that includes academic institutions, biotechnology companies, and pharmaceutical firms, primarily serving markets in North America, Europe, and Asia.

By allowing researchers to focus on scientific inquiry rather than repetitive tasks, Cornucopia aims to significantly reduce the time and cost associated with preclinical research. Cornucopia Bio's revenue model is primarily based on subscription services that facilitate access to its laboratory automation platform. Clients engage with the company through direct partnerships, utilizing the software-as-a-service model to integrate the platform into their existing laboratory operations. Transactions typically involve an annual subscription fee that grants users access to protocol generation, execution capabilities, and ongoing support.

Revenue is driven by the adoption of these services among research labs looking to increase efficiency and reproducibility in their experiments. While specific pricing plans are tailored to the needs of different clients, the company’s flagship offerings focus on providing comprehensive solutions that cater to a variety of assay complexities. Cornucopia Biosciences plans to leverage the recent funding of USD 200,000 raised in November 2025 to enhance its automation platform and develop new products aimed at further simplifying laboratory workflows. The company is targeting expansion into additional markets in Europe and Asia by 2026, aiming to increase its presence and client base in these regions.